Clinical Trials on Influenza Type B

Total 60828 results

Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
2seventy bio

Recruiting

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Diffuse Large B Cell Lymphoma (DLBCL)

United States
Singapore General Hospital
Janssen, LP

Recruiting

RICE-ibrutinib in Relapsed DLBCL

Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent

Singapore
University of Nebraska
National Cancer Institute (NCI)

Completed

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (R2-GOD)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Dana-Farber Cancer Institute
Sanofi; Genzyme, a Sanofi Company

Terminated

Cyclophosphamide and Alemtuzumab In Lymphoma

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

United States
Pharmacyclics LLC.

Completed

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753)

B-Cell Leukemia | B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
Sociedad de Lucha Contra el Cáncer del Ecuador

Not yet recruiting

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Neoplasms | Lymphoma, B-Cell | Cancer | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Metabolomics

Ecuador
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Withdrawn

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

Italy
Zhujiang Hospital
Shenzhen Geno-Immune Medical Institute

Withdrawn

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

B-Cell Lymphoma | B-cell Non Hodgkin Lymphoma | B Cell ALL

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | NHL | High-grade B-cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Novartis Pharmaceuticals

Withdrawn

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL)
Northwestern University
National Cancer Institute (NCI); Gateway for Cancer Research

Terminated

Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission

Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
Peking Union Medical College Hospital

Recruiting

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Diffuse Large B Cell Lymphoma | Radiotherapy | CAR-T | Bridging Therapy

China
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Lymphoma

Italy
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Conditioning | Diffuse Large B-cell Lymphoma | Autologous Hematopoietic Stem Cell Transplantation

China
Ruijin Hospital

Not yet recruiting

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Relapsed or Refractory B-cell Lymphoma

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

China
Pfizer
Hoffmann-La Roche

Recruiting

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

United States, Taiwan, Japan, Israel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

China
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B-Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
The First Affiliated Hospital of Soochow University

Recruiting

Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Diffuse Large B-Cell Lymphoma

China
Sun Yat-sen University

Not yet recruiting

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (O-Gemox)

DLBCL

China
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
Peking Union Medical College Hospital

Recruiting

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Intravascular Large B-Cell Lymphoma

China
University of Rochester

Recruiting

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DLBCL

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

United States, France, Spain, Italy
Mabion SA

Completed

MabionCD20 Compared to MabThera in Lymphoma Patients (MADILYM)

Diffuse Large B-Cell Lymphoma

Serbia, Poland, Croatia, Bosnia and Herzegovina, Georgia, Moldova, Republic of, Ukraine
Patrick Reagan
Seagen Inc.

Active, not recruiting

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (BV mini CHP)

Diffuse Large B-Cell Lymphoma

United States
Incyte Corporation

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Herlev Hospital

Completed

Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA

Lymphoma, Large B-Cell, Diffuse

Denmark
M.D. Anderson Cancer Center
Genentech, Inc.; Celgene

Completed

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Lymphoma

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
Incyte Corporation

Completed

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Lymphoma

United States, Spain, Korea, Republic of, Belgium, Australia, Czechia, Poland, Canada, France, Italy, United Kingdom
University Hospital, Montpellier

Completed

Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Lymphoma, B-Cell

France
University of Birmingham
AstraZeneca; Cancer Research UK; Bloodwise

Completed

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (TORCH)

Diffuse Large B-Cell Lymphoma

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma

Lymphoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Genentech, Inc.

Completed

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Lymphoma, B-Cell

United States
Hoffmann-La Roche

Completed

An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse Large B-Cell Lymphoma

China

Clinical Trials on Influenza Type B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations